Table 4 Antimicrobial susceptibility of Gram-positive isolates
|  | CoNS (N = 37) | Streptococcus pneumoniae (N = 5) | Enterococcus faecium (N = 5) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | n | S | I | R | n | S | I | R | n | S | I | R |
Penicillin | 37 | 1 (2.7%) | Â | 36 (97.3%) | 5 | 2 (40%) | Â | 3 (60%) | 5 | Â | Â | 5 (100%) |
Oxacillin | 37 | 7 (18.9%) |  | 30 (81.1%) | – |  |  |  | – |  |  |  |
Ampicillin | – |  |  |  | – |  |  |  | 5 |  |  | 5 (100%) |
Amoxicillin-Clavulanate | 34 | 7 (20.6%) |  | 27 (79.4%) | – |  |  |  | – |  |  |  |
Cefazolin | 28 | 4 (14.3%) |  | 24 (85.7%) | – |  |  |  | – |  |  |  |
Ciprofloxacin | 16 | 5 (31.3%) |  | 11 (68.8%) | – |  |  |  | 5 |  |  | 5 (100%) |
Levofloxacin | 20 | 8 (40%) | 5 (25%) | 7 (35%) | 5 | 5 (100%) |  |  | – |  |  |  |
Moxifloxacin | 6 | 3 (50%) | 1(16.7%) | 2(33.3%) | 5 | 5 (100%) |  |  | – |  |  |  |
Tetracycline | 36 | 27 (75%) | Â | 9 (25%) | 5 | Â | 1 (20%) | 4 (80%) | 5 | 3 (60%) | Â | 2 (40%) |
Erythrocin | 37 | 4 (10.8%) |  | 33 (89.2%) | 5 |  | 1 (20%) | 4 (80%) | – |  |  |  |
Clindamycin | 37 | 14 (37.8%) | 7 (18.9%) | 16 (43.2%) | 3 |  |  | 3 (100%) | – |  |  |  |
Chloramphenicol | – |  |  |  | 5 | 4 (80%) |  | 1 (20%) | 5 | 3 (60%) | 2 (40%) |  |
Rifampicin | 35 | 28 (80%) | Â | 7 (20%) | 2 | 2 (100%) | Â | Â | 5 | 1 (20%) | Â | 4 (80%) |
Compound Sulfamethoxazole | 37 | 9 (24.3%) |  | 28 (75.7%) | 5 | 2 (40%) | 1 (20%) | 2 (40%) | – |  |  |  |
Gentamicin | 37 | 21 (56.8%) | 1 (2.7%) | 15 (40.5%) | – |  |  |  | 5 | 1 (20%) |  | 4 (80%) |
Vancomycin | 37 | 37 (100%) | Â | Â | 5 | 5 (100%) | Â | Â | 5 | 5 (100%) | Â | Â |
Teicoplanin | 37 | 37 (100%) | Â | Â | 5 | 5 (100%) | Â | Â | 5 | 5 (100%) | Â | Â |
Linezolid | 37 | 37 (100%) | Â | Â | 2 | 2 (100%) | Â | Â | 5 | 5 (100%) | Â | Â |